SLC1A1 and amyotrophic lateral sclerosis: Interestingly, Riluzol, the only drug approved by the European Medical Agency for the treatment of ALS with a small significant effect on survival, has been reported to augment EAAT3 expression and decrease ROS in C6 astroglial cells [73].